Astria joins Kaken to bring new HAE therapy navenibart to Japan
Kaken Pharmaceutical has secured the rights to develop and commercialize navenibart, an investigational treatment for hereditary angioedema (HAE), in Japan. Kaken will pay $16 million as part of an agreement with navenibart developer Astria Therapeutics that includes another $16 million if development and sales milestones are…